3,315 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by John G Ullman & Associates Inc.

John G Ullman & Associates Inc. bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the fourth quarter, HoldingsChannel.com reports. The firm bought 3,315 shares of the biopharmaceutical company’s stock, valued at approximately $2,361,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of REGN. Rakuten Securities Inc. grew its position in Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares during the last quarter. FSA Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $26,000. Private Wealth Management Group LLC grew its holdings in shares of Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 39 shares during the last quarter. Truvestments Capital LLC bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $39,000. Finally, Valley Wealth Managers Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $49,000. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on REGN shares. TD Cowen reduced their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. Citigroup lowered their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Finally, Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $698.74 on Friday. The firm has a market cap of $76.39 billion, a price-to-earnings ratio of 18.25, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The business has a 50-day moving average price of $698.51 and a 200-day moving average price of $868.16. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the company earned $11.86 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s payout ratio is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.